About 5'-3' exonuclease PLD3
5'-3' exonuclease PLD3 (PLD3) is a protein
from Homo sapiens identified by UniProt accession
Q8IV08, 490 residues long.
MolForge cross-references it against 0 known binders and
153 disease associations.
Target properties
| Protein name | 5'-3' exonuclease PLD3 |
| UniProt accession | Q8IV08 |
| Gene | PLD3 |
| Organism | Homo sapiens |
| Length | 490 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (153)
Diseases linked to this target (Open Targets).
- Autosomal dominant cerebellar ataxia type 1 · score 0.48
- breast adenocarcinoma · score 0.25
- endometrial cancer · score 0.23
- head and neck squamous cell carcinoma · score 0.21
- neurodegenerative disease · score 0.17
- Alzheimer disease · score 0.11
- prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- Familial prostate cancer · score 0.11
- blood protein measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IV08-F1 | alphafold | PREDICTED | 91.18 | — |
Amino-acid sequence (490 residues)
MKPKLMYQEL KVPAEEPANE LPMNEIEAWK AAEKKARWVL LVLILAVVGF GALMTQLFLW EYGDLHLFGP NQRPAPCYDP CEAVLVESIP EGLDFPNAST GNPSTSQAWL GLLAGAHSSL DIASFYWTLT NNDTHTQEPS AQQGEEVLRQ LQTLAPKGVN VRIAVSKPSG PQPQADLQAL LQSGAQVRMV DMQKLTHGVL HTKFWVVDQT HFYLGSANMD WRSLTQVKEL GVVMYNCSCL ARDLTKIFEA YWFLGQAGSS IPSTWPRFYD TRYNQETPME ICLNGTPALA YLASAPPPLC PSGRTPDLKA LLNVVDNARS FIYVAVMNYL PTLEFSHPHR FWPAIDDGLR RATYERGVKV RLLISCWGHS EPSMRAFLLS LAALRDNHTH SDIQVKLFVV PADEAQARIP YARVNHNKYM VTERATYIGT SNWSGNYFTE TAGTSLLVTQ NGRGGLRSQL EAIFLRDWDS PYSHDLDTSA DSVGNACRLL
Explore 5'-3' exonuclease PLD3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets